Branded

Roche's Hemlibra offers a new subcutaneous administration once weekly, every two weeks or every four weeks.

Leadiant Bioscience has received the FDA's nod for a new enzyme replacement therapy for ADA-SCID, an ultrarare genetic disorder.

Eisai has received the FDA's approval for an expanded indication of Fycompa in pediatric patients age 4 years old and older who have seizures.

Eli Lilly's FDA approval for Emgality is bringing a new preventive treatment of migraine to adults.

The Food and Drug Administration approved Copiktra for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma.

The Food and Drug Administration approved Teva Pharmaceutical's Ajovy, which is indicated for the preventive treatment of migraine in adults.

Hikma Pharmaceuticals has launched Adriamycin for injection, which is indicated for the treatment of such cancers as acute lymphoblastic leukemia, acute myeloblastic leukemia and metastatic breast cancer.

Sun Pharma's Xelpros, approved by the FDA, is the first and only form of latanoprost that is not formulated with benzalkonium chloride (BAK), a preservative commonly used in topical ocular preparations.